# C4 Therapeutics

reported initial Phase 1 first-in-human results for cemsidomide (CFT7455), a novel MonoDAC IKZF1/3 degrader, in patients with non-Hodgkin's lymphoma.

Source: https://en.bioecon.ru/companies/c4-therapeutics/
Updated: 2026-07-20

- Country: United States
- Ticker: CCCC

## Technologies

- [PROTACs (targeted protein degradation)](https://en.bioecon.ru/technology/protacs/)